Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
about
Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.Propagation of TEM- and PSE-type beta-lactamases among amoxicillin-resistant Salmonella spp. isolated in France.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates.Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.Extended-spectrum beta-lactamases (ESbLs): characterization, epidemiology and detection.No Development of Imipenem Resistance in Pneumonia Caused by Escherichia coli.Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinationsEffect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase.Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.Patterns of resistance to beta-lactams and characterization of beta-lactamases in Escherichia coli isolates from children in Tunisia.Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase.Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial.Prevalence of plasmid-mediated AmpC β-lactamases in Escherichia coli and Klebsiella pneumonia at tertiary care hospital of Islamabad, Pakistan.SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group.Sepsis National Hospital Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate Antibiotics for the Treatment of Sepsis.In-vitro activity of ciprofloxacin and sixteen other antimicrobial agents against blood culture isolates.Beta-lactamase patterns and betalactam/clavulanic acid resistance in Escherichia coli isolated from fecal samples from healthy volunteers.
P2860
Q33750810-123A3030-7FCD-440F-A512-497722FD1FE2Q33977839-1DE9F8D4-EAE6-458D-8753-37766CC601BAQ34042624-49DF1197-747B-4563-8137-8E7EAE3AACCDQ35120245-B9E45B4A-FC8F-4FBF-8136-EA09BDDFF9DCQ35126478-6CBF8911-7E46-4209-AE33-4558A3FEA80DQ35132969-405FECDA-C837-486A-8524-3621D230CC9DQ35760054-1E60CDBD-D6EA-40AF-9699-E9FF5F0C1E66Q35857774-809F7A3F-CDFF-4726-ABAF-74EA88758F13Q36753170-8EAD6074-8358-4790-9158-CDA4B7C25F1FQ36756431-C089E305-2F37-42A4-896F-5EADF50ADCA3Q37514259-9499ED4F-3FF8-470B-B9AA-178473ACE04BQ39416360-38E4D4B7-C9A3-4E23-BD14-DEAC713AE1FCQ39866597-5C63999E-1A59-4421-96A3-F6BB48A27946Q40087113-79167540-9F85-4709-87E1-589FCAB84EA0Q40285545-5A5A58A0-0EDD-4C3C-9912-ED7CFC31914DQ40471195-4589C300-DE53-48E0-B1C6-39A7B40682ABQ40670277-4AC3A44D-4507-4795-9BC4-EC5A48CD5204Q42150778-FC9AEB7A-1C4E-4E54-9333-EC4517A57794Q42184834-50E78B87-A89E-4A59-97AC-8B7EC8230730Q42595403-ABA2FCCC-2FAE-4501-8B11-DEFE75FC031DQ45070457-9E00DA65-A2A8-44BE-A028-5F7A3ADDC315Q50164239-6BBA7CBE-8C51-4F0D-A75F-D75B2DA132BEQ54045958-69AD9C90-31BB-4E8F-96F5-B75FD260393E
P2860
Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
description
1990 nî lūn-bûn
@nan
1990 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@ast
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@en
type
label
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@ast
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@en
prefLabel
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@ast
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@en
P2093
P2860
P356
P1476
Beta-lactamase production in m ...... enzyme inhibitor combinations.
@en
P2093
Sanders CC
Sanders WE Jr
Thomson KS
P2860
P304
P356
10.1128/AAC.34.4.622
P407
P577
1990-04-01T00:00:00Z